Disc Medicine, Inc. - IRON STOCK NEWS

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that its CEO, John Quisel, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on May 2, 2023, at 2:30 p.m. ET. The event aims to highlight the company's innovative treatments for serious hematologic diseases, focusing on red blood cell biology and iron homeostasis.

The fireside chat will be accessible via a live webcast on the investor relations section of the company's website, with an archived replay available post-event. Disc Medicine is dedicated to developing novel therapies targeting fundamental biological pathways in hematologic diseases.

Disc Medicine, a clinical-stage biopharmaceutical company (NASDAQ:IRON), announced a virtual KOL investor event scheduled for April 25, 2023, to discuss erythropoietic protoporphyria (EPP). This rare and severe disease is caused by mutations in the heme biosynthesis pathway. The event will feature presentations from experts who will address the disease's epidemiology, pathophysiology, and unmet patient needs. Leadership will also outline development plans for bitopertin, an investigational therapy aimed at treating EPP. Currently, there is no cure for EPP, and only one FDA-approved treatment exists. The event will be webcast live, with a replay available for 90 days. For further details, visit Disc's investor webpage.

Disc Medicine, a clinical-stage biopharmaceutical company, completed a reverse merger with Gemini Therapeutics and debuted on Nasdaq as IRON. It ended 2022 with approximately $194.6 million in cash and cash equivalents. The company has initiated two Phase 2 trials for bitopertin targeting erythropoietic protoporphyria and expects initial data in 2023. Additionally, it completed a Phase 1 study of DISC-0974 and began new studies in patients with myelofibrosis and chronic kidney disease. The net loss for 2022 was $46.8 million, up from $36.0 million in 2021, due to increased operating costs.

Disc Medicine (NASDAQ:IRON) announced its collaboration with the National Heart Lung and Blood Institute to conduct a phase 2 clinical trial of bitopertin in patients with Diamond-Blackfan anemia (DBA). This trial aims to evaluate the efficacy of bitopertin, an investigational drug designed to modulate heme biosynthesis, which could potentially address heme accumulation in DBA patients. The study will be sponsored by the NHLBI and is anticipated to begin in mid-2023. DBA is a rare inherited blood disorder characterized by severely reduced red blood cell production, often requiring lifelong management.

Disc Medicine has initiated a multi-center Phase 1b/2 clinical study for its investigational monoclonal antibody, DISC-0974, targeting anemia in non-dialysis dependent chronic kidney disease (NDD-CKD) patients. The therapy aims to suppress hepcidin levels, enhancing iron availability for erythropoiesis. This study follows earlier trials demonstrating proof-of-mechanism, and also includes ongoing investigations in myelofibrosis patients. The trial will evaluate safety, tolerability, and efficacy, focusing on hepcidin levels and hemoglobin changes. As of now, DISC-0974 remains investigational and is not yet approved for clinical use.

Disc Medicine, Inc. (NASDAQ: IRON) announced a securities purchase agreement yielding $62.5 million in gross proceeds from a registered direct offering. The financing was led by Bain Capital Life Sciences, contributing $50 million, alongside existing investors Access Biotechnology and OrbiMed. The offering includes 1,488,166 shares at $23.00 per share and pre-funded warrants for 1,229,224 shares at $22.9999. The investment will primarily support Disc’s clinical pipeline, which includes three investigational therapies targeting severe hematologic diseases, expected to yield critical clinical trial data mid-2023.

Disc Medicine, Inc. (NASDAQ:IRON), a clinical-stage biopharmaceutical company, announced that CEO John Quisel will participate in a fireside chat at the SVB Securities Global Biopharma Conference on February 16, 2023, at 8:40 a.m. ET. The event will be held virtually, and a live webcast can be accessed via the investor relations section of the company's website. Disc Medicine focuses on developing novel treatments for serious hematologic diseases, targeting key biological pathways, including heme biosynthesis and iron homeostasis. For further details, visit the company's website.

Disc Medicine has secured exclusive rights to MWTX-003, an anti-TMPRSS6 antibody, following an agreement with Mabwell Therapeutics. This drug, which shows promise in treating beta-thalassemia and polycythemia vera, has received FDA acceptance for its Investigational New Drug (IND) application. A phase 1 study is set to commence in the second half of 2023. The agreement includes a $10 million upfront payment, with potential total payments reaching $412.5 million, plus royalties on sales. Disc's focus is on developing treatments for serious hematologic diseases through innovation in iron homeostasis.